The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, US. [Reuters]
Johnson & Johnson (JNJ.N) said on Monday its Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.